Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Q32 Bio Inc., 3 years.
Q32 Bio Inc.
Director
CervoMed Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Grant or award | +15,117 | — | — |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −350 | $242.37 | $84,830 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −382 | $243.36 | $92,964 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −258 | $244.41 | $63,058 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −189 | $245.26 | $46,354 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −77 | $246.18 | $18,956 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −7 | $247.35 | $1,731 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1 | $248.36 | $248 |
| Feb 28, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −42 | $236.51 | $9,933 |
| Feb 28, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −34 | $238.33 | $8,103 |
| Feb 28, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −35 | $239.18 | $8,371 |
| Feb 28, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −78 | $240.32 | $18,745 |
| Feb 28, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −127 | $241.51 | $30,672 |
| Feb 28, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −300 | $242.44 | $72,732 |
| Feb 28, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −121 | $243.23 | $29,431 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.